NO20073369L - Modulatorer av muskarinreseptorer - Google Patents
Modulatorer av muskarinreseptorerInfo
- Publication number
- NO20073369L NO20073369L NO20073369A NO20073369A NO20073369L NO 20073369 L NO20073369 L NO 20073369L NO 20073369 A NO20073369 A NO 20073369A NO 20073369 A NO20073369 A NO 20073369A NO 20073369 L NO20073369 L NO 20073369L
- Authority
- NO
- Norway
- Prior art keywords
- modulators
- muscarinic receptors
- present
- muscarinic
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63140304P | 2004-11-29 | 2004-11-29 | |
PCT/US2005/042967 WO2006058303A2 (en) | 2004-11-29 | 2005-11-29 | Modulators of muscarinic receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073369L true NO20073369L (no) | 2007-08-29 |
Family
ID=36218698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073369A NO20073369L (no) | 2004-11-29 | 2007-06-29 | Modulatorer av muskarinreseptorer |
Country Status (14)
Country | Link |
---|---|
US (1) | US7863449B2 (zh) |
EP (1) | EP1817036B1 (zh) |
JP (1) | JP2008521825A (zh) |
KR (1) | KR20070086756A (zh) |
CN (1) | CN101155587A (zh) |
AU (1) | AU2005309365B2 (zh) |
CA (1) | CA2589439A1 (zh) |
IL (1) | IL183478A0 (zh) |
MX (1) | MX2007006382A (zh) |
NO (1) | NO20073369L (zh) |
NZ (1) | NZ555444A (zh) |
RU (1) | RU2007124373A (zh) |
WO (1) | WO2006058303A2 (zh) |
ZA (1) | ZA200705116B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507800A (ja) | 2005-09-09 | 2009-02-26 | ユーロ−セルティーク エス.エイ. | 縮合およびスピロ環化合物ならびにその使用 |
US7786107B2 (en) * | 2006-08-18 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
US8927715B2 (en) * | 2006-08-25 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
EP2079694B1 (en) * | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
AU2007342368A1 (en) | 2007-01-04 | 2008-07-17 | Merck & Co., Inc. | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease |
WO2008121066A1 (en) * | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
US8383629B2 (en) * | 2008-02-27 | 2013-02-26 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
WO2016177472A1 (en) * | 2015-05-05 | 2016-11-10 | Laboratorios Del Dr. Esteve, S.A. | Spiro-isoquinoline-4,4'-piperidine compounds having multimodal activity against pain |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654287A (en) * | 1970-08-26 | 1972-04-04 | Mead Johnson & Co | Spiroindanylpiperidines |
US3666764A (en) * | 1970-08-26 | 1972-05-30 | Mead Johnson & Co | Spiroindenylpiperidines |
US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
US3959475A (en) * | 1973-12-12 | 1976-05-25 | American Hoechst Corporation | Substituted 1,3-dihydrospiro(isobenzofuran)s |
US4409229A (en) * | 1977-12-02 | 1983-10-11 | Hoechst-Roussel Pharmaceuticals, Inc. | Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s |
JPS54109983A (en) * | 1978-02-13 | 1979-08-29 | Sumitomo Chem Co Ltd | Novel spiroamine derivative and its preparation |
GB1575800A (en) | 1978-05-16 | 1980-10-01 | Sumitomo Chemical Co | Spiro amines their production and compositions containing them |
US4349549A (en) * | 1981-05-18 | 1982-09-14 | Syntex (U.S.A.) Inc. | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s |
JPS5815979A (ja) | 1981-07-11 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体およびその製造法 |
JPS5959685A (ja) | 1982-09-28 | 1984-04-05 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
US4558049A (en) * | 1982-11-24 | 1985-12-10 | Farmitalia Carlo Erba S.P.A. | Antipsycotic benzoxazines |
SE445649B (sv) * | 1983-06-08 | 1986-07-07 | Jorgen Hermansson | Anvendning av en fast berare med immobiliserad orosomucoid for separation, forfarande for framstellning av separationsmaterial, separationsanordning samt separationsmaterial |
GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
EP0444945A3 (en) | 1990-03-02 | 1992-05-13 | Merck & Co. Inc. | Use of spirocyclic compounds as oxytocin antagonists |
US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
EP0445974A3 (en) * | 1990-03-05 | 1992-04-29 | Merck Sharp & Dohme Ltd. | Spirocyclic antipsychotic agents |
IL99957A0 (en) | 1990-11-13 | 1992-08-18 | Merck & Co Inc | Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
US5693643A (en) * | 1991-09-16 | 1997-12-02 | Merck & Co., Inc. | Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
DK78692D0 (da) * | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | Dimere piperidin- og piperazinderivater |
RU2168512C2 (ru) * | 1992-12-11 | 2001-06-10 | Мерк Энд Ко., Инк. | Спиропиперидины, способы их получения (варианты) |
US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
US5457207A (en) * | 1993-10-05 | 1995-10-10 | Regents Of The University Of Minnesota | Spirovesamicols |
KR960705575A (ko) | 1993-10-19 | 1996-11-08 | 도나 엘. 폴락 | 비스포스포네이트와 성장 호르몬 분비촉진제와의 배합물(Combination of bishosphonates and growth hormone secretagogues) |
AU687953B2 (en) | 1993-11-16 | 1998-03-05 | Merck & Co., Inc. | Piperidinylcamphorsulfonyl oxytocin antagonists |
WO1995028389A1 (fr) | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5741789A (en) * | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5789402A (en) * | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
GB2308064A (en) | 1995-10-31 | 1997-06-18 | Merck & Co Inc | Treatment of congestive heart failure with a growth hormone secretagogue |
GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
EP0900086A4 (en) | 1996-05-07 | 2000-01-12 | Merck & Co Inc | IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES |
AU2931997A (en) | 1996-05-07 | 1997-11-26 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
CA2290750A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6013652A (en) * | 1997-12-04 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin antagonists |
AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
GB9810886D0 (en) * | 1998-05-13 | 1998-07-22 | Lilly Industries Ltd | Pharmaceutical compounds |
US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
JP2002521436A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | 置換アニリド化合物および方法 |
JP2002521441A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | Ccr5モジュレーターとしてのプロペンアミド |
AU1691500A (en) | 1998-12-24 | 2000-07-31 | Meiji Seika Kaisha Ltd. | Remedies for pain |
ITMI991452A1 (it) | 1999-07-01 | 2001-01-01 | Mediolanum Farmaceutici Srl | Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica |
US6803372B2 (en) | 1999-08-20 | 2004-10-12 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
JP3411262B2 (ja) * | 1999-08-20 | 2003-05-26 | 萬有製薬株式会社 | 新規スピロ化合物 |
AU7716600A (en) | 1999-09-30 | 2001-04-30 | Merck & Co., Inc. | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof |
GB2355264A (en) * | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) * | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
AU7952800A (en) | 1999-10-22 | 2001-04-30 | Sankyo Company Limited | 2-alkoxybenzene derivatives |
WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2001243394A1 (en) | 2000-03-02 | 2001-09-12 | Smith Kline Beecham Corporation | Compounds and methods |
JP2001278886A (ja) | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
US6720324B2 (en) * | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
ATE310004T1 (de) * | 2000-12-12 | 2005-12-15 | Neurogen Corp | Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine |
WO2002079146A2 (en) * | 2001-03-02 | 2002-10-10 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
US6828440B2 (en) * | 2001-04-18 | 2004-12-07 | Euro-Celtique, S.A. | Spiroindene and spiroindane compounds |
JP2002316987A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | 2−アルコキシベンゼン誘導体を含有する医薬 |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
BRPI0104510B8 (pt) | 2001-07-27 | 2021-05-25 | Embrapa Pesquisa Agropecuaria | peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada |
US7205417B2 (en) * | 2001-08-07 | 2007-04-17 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
WO2003037271A2 (en) * | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
JP2005519921A (ja) * | 2002-01-28 | 2005-07-07 | ファイザー株式会社 | Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物 |
JPWO2003095427A1 (ja) * | 2002-05-10 | 2005-09-15 | 大正製薬株式会社 | スピロ環化合物 |
US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
GB0213715D0 (en) * | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
US7105526B2 (en) * | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
UA77814C2 (en) * | 2002-07-03 | 2007-01-15 | Lundbeck & Co As H | Spirocyclic piperidines as antagonists of mch1 and use thereof |
WO2004011427A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
AU2003256923A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
WO2004010942A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
DK1562595T3 (da) * | 2002-09-19 | 2008-08-18 | Lilly Co Eli | Diarylethere som opioidreceptorantagonister |
US7045527B2 (en) * | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
AU2003302640B2 (en) * | 2002-11-29 | 2009-09-24 | Banyu Pharmaceutical Co., Ltd. | Novel azole derivatives |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
AU2004222336B2 (en) * | 2003-03-18 | 2010-06-03 | Merck Sharp & Dohme Corp. | Amino cyclobutylamide modulators of chemokine receptor activity |
AU2004227835B2 (en) * | 2003-04-04 | 2007-06-14 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
CN1297557C (zh) | 2003-04-10 | 2007-01-31 | 上海药明康德新药开发有限公司 | 螺环类模板化合物的制备 |
JP4679514B2 (ja) * | 2003-04-24 | 2011-04-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Akt活性の阻害剤 |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
PL1696931T3 (pl) * | 2003-12-22 | 2009-10-30 | Acadia Pharm Inc | Aminopodstawione analogi diarylo[A,D]cykloheptenowe jako agoniści receptorów muskarynowych i sposoby leczenia chorób neuropsychiatrycznych |
AU2004309419A1 (en) * | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
RU2006132465A (ru) * | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Модуляторы хемокинового рецептора ccr5 |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
EP1789409A4 (en) * | 2004-04-02 | 2010-09-08 | Elixir Pharmaceuticals Inc | SULPHONAMIDES AND ITS USES |
US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
US7786141B2 (en) * | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
EP1795527B1 (en) * | 2004-09-07 | 2009-04-22 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
-
2005
- 2005-11-29 CN CNA2005800471348A patent/CN101155587A/zh active Pending
- 2005-11-29 AU AU2005309365A patent/AU2005309365B2/en not_active Ceased
- 2005-11-29 RU RU2007124373/04A patent/RU2007124373A/ru not_active Application Discontinuation
- 2005-11-29 MX MX2007006382A patent/MX2007006382A/es active IP Right Grant
- 2005-11-29 US US11/288,939 patent/US7863449B2/en active Active
- 2005-11-29 JP JP2007543577A patent/JP2008521825A/ja active Pending
- 2005-11-29 WO PCT/US2005/042967 patent/WO2006058303A2/en active Application Filing
- 2005-11-29 EP EP05852309A patent/EP1817036B1/en active Active
- 2005-11-29 KR KR1020077014774A patent/KR20070086756A/ko not_active Application Discontinuation
- 2005-11-29 NZ NZ555444A patent/NZ555444A/en not_active IP Right Cessation
- 2005-11-29 CA CA002589439A patent/CA2589439A1/en not_active Abandoned
-
2007
- 2007-05-28 IL IL183478A patent/IL183478A0/en unknown
- 2007-06-18 ZA ZA200705116A patent/ZA200705116B/xx unknown
- 2007-06-29 NO NO20073369A patent/NO20073369L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070086756A (ko) | 2007-08-27 |
CA2589439A1 (en) | 2006-06-01 |
AU2005309365B2 (en) | 2011-10-06 |
JP2008521825A (ja) | 2008-06-26 |
US7863449B2 (en) | 2011-01-04 |
NZ555444A (en) | 2011-01-28 |
IL183478A0 (en) | 2007-09-20 |
RU2007124373A (ru) | 2009-01-10 |
EP1817036A2 (en) | 2007-08-15 |
US20060270653A1 (en) | 2006-11-30 |
WO2006058303A3 (en) | 2006-12-21 |
WO2006058303A2 (en) | 2006-06-01 |
EP1817036B1 (en) | 2012-07-04 |
MX2007006382A (es) | 2007-07-11 |
ZA200705116B (en) | 2008-06-25 |
CN101155587A (zh) | 2008-04-02 |
AU2005309365A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071272L (no) | Modulatorer av muskarine reseptorer. | |
NO20083011L (no) | Modulatorer av muskarine receptorer | |
NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
NO20073369L (no) | Modulatorer av muskarinreseptorer | |
WO2006058294A3 (en) | Modulators of muscarinic receptors | |
WO2006105035A3 (en) | Muscarinic modulators | |
NO20084878L (no) | Humanisert C-kit antistoff | |
NO20084007L (no) | Spirokondenserte piperidiner som modulatorer av muskarinreseptorer | |
NO20084006L (no) | Modulatorer av muskarinreseptorer | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
ATE473744T1 (de) | Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
DK1836169T3 (da) | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser | |
NO20070487L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
ATE421518T1 (de) | Dihydrochinazolinone als 5ht-modulatoren | |
DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
ATE538650T1 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
NO20081788L (no) | Cyklopropylaminer som modulatorer av histamin-H3-reseptoren | |
DE602005014566D1 (de) | Chinolinon-carboxamid-verbindungen | |
WO2008021375A3 (en) | Modulators of muscarinic receptors | |
NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
EA200601267A1 (ru) | Модуляторы рецепторов андрогена |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |